Table of Content

1 Diabetic Neuropathic Pain Drug Market Overview
1.1 Product Overview and Scope of Diabetic Neuropathic Pain Drug
1.2 Diabetic Neuropathic Pain Drug Segment by Type
1.2.1 Global Diabetic Neuropathic Pain Drug Market Value Comparison by Type (2024-2034)
1.2.2 AZD-5213
1.2.3 Clonidine Hydrochloride
1.2.4 Duloxetine Hydrochloride DR
1.2.5 E-52862
1.2.6 Filgrastim
1.2.7 GERPOOI
1.2.8 GRC-17536
1.2.9 Others
1.3 Diabetic Neuropathic Pain Drug Segment by Application
1.3.1 Global Diabetic Neuropathic Pain Drug Market Value by Application: (2024-2034)
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Global Diabetic Neuropathic Pain Drug Market Size Estimates and Forecasts
1.4.1 Global Diabetic Neuropathic Pain Drug Revenue 2018-2034
1.4.2 Global Diabetic Neuropathic Pain Drug Sales 2018-2034
1.4.3 Global Diabetic Neuropathic Pain Drug Market Average Price (2018-2034)
1.5 Assumptions and Limitations
2 Diabetic Neuropathic Pain Drug Market Competition by Manufacturers
2.1 Global Diabetic Neuropathic Pain Drug Sales Market Share by Manufacturers (2018-2024)
2.2 Global Diabetic Neuropathic Pain Drug Revenue Market Share by Manufacturers (2018-2024)
2.3 Global Diabetic Neuropathic Pain Drug Average Price by Manufacturers (2018-2024)
2.4 Global Diabetic Neuropathic Pain Drug Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Diabetic Neuropathic Pain Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Diabetic Neuropathic Pain Drug, Product Type & Application
2.7 Diabetic Neuropathic Pain Drug Market Competitive Situation and Trends
2.7.1 Diabetic Neuropathic Pain Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Diabetic Neuropathic Pain Drug Players Market Share by Revenue
2.7.3 Global Diabetic Neuropathic Pain Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Diabetic Neuropathic Pain Drug Retrospective Market Scenario by Region
3.1 Global Diabetic Neuropathic Pain Drug Market Size by Region: 2018 Versus 2022 Versus 2034
3.2 Global Diabetic Neuropathic Pain Drug Global Diabetic Neuropathic Pain Drug Sales by Region: 2018-2034
3.2.1 Global Diabetic Neuropathic Pain Drug Sales by Region: 2018-2024
3.2.2 Global Diabetic Neuropathic Pain Drug Sales by Region: 2024-2034
3.3 Global Diabetic Neuropathic Pain Drug Global Diabetic Neuropathic Pain Drug Revenue by Region: 2018-2034
3.3.1 Global Diabetic Neuropathic Pain Drug Revenue by Region: 2018-2024
3.3.2 Global Diabetic Neuropathic Pain Drug Revenue by Region: 2024-2034
3.4 North America Diabetic Neuropathic Pain Drug Market Facts & Figures by Country
3.4.1 North America Diabetic Neuropathic Pain Drug Market Size by Country: 2018 VS 2022 VS 2034
3.4.2 North America Diabetic Neuropathic Pain Drug Sales by Country (2018-2034)
3.4.3 North America Diabetic Neuropathic Pain Drug Revenue by Country (2018-2034)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Diabetic Neuropathic Pain Drug Market Facts & Figures by Country
3.5.1 Europe Diabetic Neuropathic Pain Drug Market Size by Country: 2018 VS 2022 VS 2034
3.5.2 Europe Diabetic Neuropathic Pain Drug Sales by Country (2018-2034)
3.5.3 Europe Diabetic Neuropathic Pain Drug Revenue by Country (2018-2034)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Diabetic Neuropathic Pain Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Diabetic Neuropathic Pain Drug Market Size by Country: 2018 VS 2022 VS 2034
3.6.2 Asia Pacific Diabetic Neuropathic Pain Drug Sales by Country (2018-2034)
3.6.3 Asia Pacific Diabetic Neuropathic Pain Drug Revenue by Country (2018-2034)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Diabetic Neuropathic Pain Drug Market Facts & Figures by Country
3.7.1 Latin America Diabetic Neuropathic Pain Drug Market Size by Country: 2018 VS 2022 VS 2034
3.7.2 Latin America Diabetic Neuropathic Pain Drug Sales by Country (2018-2034)
3.7.3 Latin America Diabetic Neuropathic Pain Drug Revenue by Country (2018-2034)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Diabetic Neuropathic Pain Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Diabetic Neuropathic Pain Drug Market Size by Country: 2018 VS 2022 VS 2034
3.8.2 Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Country (2018-2034)
3.8.3 Middle East and Africa Diabetic Neuropathic Pain Drug Revenue by Country (2018-2034)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Diabetic Neuropathic Pain Drug Sales by Type (2018-2034)
4.1.1 Global Diabetic Neuropathic Pain Drug Sales by Type (2018-2024)
4.1.2 Global Diabetic Neuropathic Pain Drug Sales by Type (2024-2034)
4.1.3 Global Diabetic Neuropathic Pain Drug Sales Market Share by Type (2018-2034)
4.2 Global Diabetic Neuropathic Pain Drug Revenue by Type (2018-2034)
4.2.1 Global Diabetic Neuropathic Pain Drug Revenue by Type (2018-2024)
4.2.2 Global Diabetic Neuropathic Pain Drug Revenue by Type (2024-2034)
4.2.3 Global Diabetic Neuropathic Pain Drug Revenue Market Share by Type (2018-2034)
4.3 Global Diabetic Neuropathic Pain Drug Price by Type (2018-2034)
5 Segment by Application
5.1 Global Diabetic Neuropathic Pain Drug Sales by Application (2018-2034)
5.1.1 Global Diabetic Neuropathic Pain Drug Sales by Application (2018-2024)
5.1.2 Global Diabetic Neuropathic Pain Drug Sales by Application (2024-2034)
5.1.3 Global Diabetic Neuropathic Pain Drug Sales Market Share by Application (2018-2034)
5.2 Global Diabetic Neuropathic Pain Drug Revenue by Application (2018-2034)
5.2.1 Global Diabetic Neuropathic Pain Drug Revenue by Application (2018-2024)
5.2.2 Global Diabetic Neuropathic Pain Drug Revenue by Application (2024-2034)
5.2.3 Global Diabetic Neuropathic Pain Drug Revenue Market Share by Application (2018-2034)
5.3 Global Diabetic Neuropathic Pain Drug Price by Application (2018-2034)
6 Key Companies Profiled
6.1 Astellas Pharma Inc.
6.1.1 Astellas Pharma Inc. Corporation Information
6.1.2 Astellas Pharma Inc. Description and Business Overview
6.1.3 Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
6.1.4 Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Product Portfolio
6.1.5 Astellas Pharma Inc. Recent Developments/Updates
6.2 AstraZeneca Plc
6.2.1 AstraZeneca Plc Corporation Information
6.2.2 AstraZeneca Plc Description and Business Overview
6.2.3 AstraZeneca Plc Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
6.2.4 AstraZeneca Plc Diabetic Neuropathic Pain Drug Product Portfolio
6.2.5 AstraZeneca Plc Recent Developments/Updates
6.3 BioDelivery Sciences International, Inc.
6.3.1 BioDelivery Sciences International, Inc. Corporation Information
6.3.2 BioDelivery Sciences International, Inc. Description and Business Overview
6.3.3 BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
6.3.4 BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Product Portfolio
6.3.5 BioDelivery Sciences International, Inc. Recent Developments/Updates
6.4 Boehringer Ingelheim GmbH
6.4.1 Boehringer Ingelheim GmbH Corporation Information
6.4.2 Boehringer Ingelheim GmbH Description and Business Overview
6.4.3 Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Product Portfolio
6.4.5 Boehringer Ingelheim GmbH Recent Developments/Updates
6.5 Daiichi Sankyo Company, Limited
6.5.1 Daiichi Sankyo Company, Limited Corporation Information
6.5.2 Daiichi Sankyo Company, Limited Description and Business Overview
6.5.3 Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
6.5.4 Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Product Portfolio
6.5.5 Daiichi Sankyo Company, Limited Recent Developments/Updates
6.6 Dong-A Socio Group
6.6.1 Dong-A Socio Group Corporation Information
6.6.2 Dong-A Socio Group Description and Business Overview
6.6.3 Dong-A Socio Group Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
6.6.4 Dong-A Socio Group Diabetic Neuropathic Pain Drug Product Portfolio
6.6.5 Dong-A Socio Group Recent Developments/Updates
6.7 Eli Lilly and Company
6.6.1 Eli Lilly and Company Corporation Information
6.6.2 Eli Lilly and Company Description and Business Overview
6.6.3 Eli Lilly and Company Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Eli Lilly and Company Diabetic Neuropathic Pain Drug Product Portfolio
6.7.5 Eli Lilly and Company Recent Developments/Updates
6.8 Glenmark Pharmaceuticals Ltd.
6.8.1 Glenmark Pharmaceuticals Ltd. Corporation Information
6.8.2 Glenmark Pharmaceuticals Ltd. Description and Business Overview
6.8.3 Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
6.8.4 Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Product Portfolio
6.8.5 Glenmark Pharmaceuticals Ltd. Recent Developments/Updates
6.9 Hydra Biosciences, Inc.
6.9.1 Hydra Biosciences, Inc. Corporation Information
6.9.2 Hydra Biosciences, Inc. Description and Business Overview
6.9.3 Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
6.9.4 Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Product Portfolio
6.9.5 Hydra Biosciences, Inc. Recent Developments/Updates
6.10 Immune Pharmaceuticals Inc.
6.10.1 Immune Pharmaceuticals Inc. Corporation Information
6.10.2 Immune Pharmaceuticals Inc. Description and Business Overview
6.10.3 Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
6.10.4 Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Product Portfolio
6.10.5 Immune Pharmaceuticals Inc. Recent Developments/Updates
6.11 Laboratorios Del Dr. Esteve S.A.
6.11.1 Laboratorios Del Dr. Esteve S.A. Corporation Information
6.11.2 Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Description and Business Overview
6.11.3 Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
6.11.4 Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Product Portfolio
6.11.5 Laboratorios Del Dr. Esteve S.A. Recent Developments/Updates
6.12 Lohocla Research Corporation
6.12.1 Lohocla Research Corporation Corporation Information
6.12.2 Lohocla Research Corporation Diabetic Neuropathic Pain Drug Description and Business Overview
6.12.3 Lohocla Research Corporation Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
6.12.4 Lohocla Research Corporation Diabetic Neuropathic Pain Drug Product Portfolio
6.12.5 Lohocla Research Corporation Recent Developments/Updates
6.13 Mertiva AB
6.13.1 Mertiva AB Corporation Information
6.13.2 Mertiva AB Diabetic Neuropathic Pain Drug Description and Business Overview
6.13.3 Mertiva AB Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
6.13.4 Mertiva AB Diabetic Neuropathic Pain Drug Product Portfolio
6.13.5 Mertiva AB Recent Developments/Updates
6.14 Novaremed
6.14.1 Novaremed Corporation Information
6.14.2 Novaremed Diabetic Neuropathic Pain Drug Description and Business Overview
6.14.3 Novaremed Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
6.14.4 Novaremed Diabetic Neuropathic Pain Drug Product Portfolio
6.14.5 Novaremed Recent Developments/Updates
6.15 Pharmaleads
6.15.1 Pharmaleads Corporation Information
6.15.2 Pharmaleads Diabetic Neuropathic Pain Drug Description and Business Overview
6.15.3 Pharmaleads Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
6.15.4 Pharmaleads Diabetic Neuropathic Pain Drug Product Portfolio
6.15.5 Pharmaleads Recent Developments/Updates
6.16 RAPID Pharmaceuticals AG
6.16.1 RAPID Pharmaceuticals AG Corporation Information
6.16.2 RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Description and Business Overview
6.16.3 RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
6.16.4 RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Product Portfolio
6.16.5 RAPID Pharmaceuticals AG Recent Developments/Updates
6.17 Relmada Therapeutics, Inc.
6.17.1 Relmada Therapeutics, Inc. Corporation Information
6.17.2 Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Description and Business Overview
6.17.3 Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
6.17.4 Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Product Portfolio
6.17.5 Relmada Therapeutics, Inc. Recent Developments/Updates
6.18 Sphaera Pharma Pvt. Ltd.
6.18.1 Sphaera Pharma Pvt. Ltd. Corporation Information
6.18.2 Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Description and Business Overview
6.18.3 Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
6.18.4 Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Product Portfolio
6.18.5 Sphaera Pharma Pvt. Ltd. Recent Developments/Updates
6.19 Theravasc, Inc.
6.19.1 Theravasc, Inc. Corporation Information
6.19.2 Theravasc, Inc. Diabetic Neuropathic Pain Drug Description and Business Overview
6.19.3 Theravasc, Inc. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
6.19.4 Theravasc, Inc. Diabetic Neuropathic Pain Drug Product Portfolio
6.19.5 Theravasc, Inc. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Diabetic Neuropathic Pain Drug Industry Chain Analysis
7.2 Diabetic Neuropathic Pain Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Diabetic Neuropathic Pain Drug Production Mode & Process
7.4 Diabetic Neuropathic Pain Drug Sales and Marketing
7.4.1 Diabetic Neuropathic Pain Drug Sales Channels
7.4.2 Diabetic Neuropathic Pain Drug Distributors
7.5 Diabetic Neuropathic Pain Drug Customers
8 Diabetic Neuropathic Pain Drug Market Dynamics
8.1 Diabetic Neuropathic Pain Drug Industry Trends
8.2 Diabetic Neuropathic Pain Drug Market Drivers
8.3 Diabetic Neuropathic Pain Drug Market Challenges
8.4 Diabetic Neuropathic Pain Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Diabetic Neuropathic Pain Drug Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Diabetic Neuropathic Pain Drug Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Diabetic Neuropathic Pain Drug Market Competitive Situation by Manufacturers in 2022
Table 4. Global Diabetic Neuropathic Pain Drug Sales (K Pcs) of Key Manufacturers (2018-2024)
Table 5. Global Diabetic Neuropathic Pain Drug Sales Market Share by Manufacturers (2018-2024)
Table 6. Global Diabetic Neuropathic Pain Drug Revenue (US$ Million) by Manufacturers (2018-2024)
Table 7. Global Diabetic Neuropathic Pain Drug Revenue Share by Manufacturers (2018-2024)
Table 8. Global Market Diabetic Neuropathic Pain Drug Average Price (USD/Pcs) of Key Manufacturers (2018-2024)
Table 9. Global Key Players of Diabetic Neuropathic Pain Drug, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Diabetic Neuropathic Pain Drug, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Diabetic Neuropathic Pain Drug, Product Type & Application
Table 12. Global Key Manufacturers of Diabetic Neuropathic Pain Drug, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Diabetic Neuropathic Pain Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Diabetic Neuropathic Pain Drug as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Diabetic Neuropathic Pain Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2034
Table 17. Global Diabetic Neuropathic Pain Drug Sales by Region (2018-2024) & (K Pcs)
Table 18. Global Diabetic Neuropathic Pain Drug Sales Market Share by Region (2018-2024)
Table 19. Global Diabetic Neuropathic Pain Drug Sales by Region (2024-2034) & (K Pcs)
Table 20. Global Diabetic Neuropathic Pain Drug Sales Market Share by Region (2024-2034)
Table 21. Global Diabetic Neuropathic Pain Drug Revenue by Region (2018-2024) & (US$ Million)
Table 22. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Region (2018-2024)
Table 23. Global Diabetic Neuropathic Pain Drug Revenue by Region (2024-2034) & (US$ Million)
Table 24. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Region (2024-2034)
Table 25. North America Diabetic Neuropathic Pain Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 26. North America Diabetic Neuropathic Pain Drug Sales by Country (2018-2024) & (K Pcs)
Table 27. North America Diabetic Neuropathic Pain Drug Sales by Country (2024-2034) & (K Pcs)
Table 28. North America Diabetic Neuropathic Pain Drug Revenue by Country (2018-2024) & (US$ Million)
Table 29. North America Diabetic Neuropathic Pain Drug Revenue by Country (2024-2034) & (US$ Million)
Table 30. Europe Diabetic Neuropathic Pain Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 31. Europe Diabetic Neuropathic Pain Drug Sales by Country (2018-2024) & (K Pcs)
Table 32. Europe Diabetic Neuropathic Pain Drug Sales by Country (2024-2034) & (K Pcs)
Table 33. Europe Diabetic Neuropathic Pain Drug Revenue by Country (2018-2024) & (US$ Million)
Table 34. Europe Diabetic Neuropathic Pain Drug Revenue by Country (2024-2034) & (US$ Million)
Table 35. Asia Pacific Diabetic Neuropathic Pain Drug Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 36. Asia Pacific Diabetic Neuropathic Pain Drug Sales by Region (2018-2024) & (K Pcs)
Table 37. Asia Pacific Diabetic Neuropathic Pain Drug Sales by Region (2024-2034) & (K Pcs)
Table 38. Asia Pacific Diabetic Neuropathic Pain Drug Revenue by Region (2018-2024) & (US$ Million)
Table 39. Asia Pacific Diabetic Neuropathic Pain Drug Revenue by Region (2024-2034) & (US$ Million)
Table 40. Latin America Diabetic Neuropathic Pain Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 41. Latin America Diabetic Neuropathic Pain Drug Sales by Country (2018-2024) & (K Pcs)
Table 42. Latin America Diabetic Neuropathic Pain Drug Sales by Country (2024-2034) & (K Pcs)
Table 43. Latin America Diabetic Neuropathic Pain Drug Revenue by Country (2018-2024) & (US$ Million)
Table 44. Latin America Diabetic Neuropathic Pain Drug Revenue by Country (2024-2034) & (US$ Million)
Table 45. Middle East & Africa Diabetic Neuropathic Pain Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 46. Middle East & Africa Diabetic Neuropathic Pain Drug Sales by Country (2018-2024) & (K Pcs)
Table 47. Middle East & Africa Diabetic Neuropathic Pain Drug Sales by Country (2024-2034) & (K Pcs)
Table 48. Middle East & Africa Diabetic Neuropathic Pain Drug Revenue by Country (2018-2024) & (US$ Million)
Table 49. Middle East & Africa Diabetic Neuropathic Pain Drug Revenue by Country (2024-2034) & (US$ Million)
Table 50. Global Diabetic Neuropathic Pain Drug Sales (K Pcs) by Type (2018-2024)
Table 51. Global Diabetic Neuropathic Pain Drug Sales (K Pcs) by Type (2024-2034)
Table 52. Global Diabetic Neuropathic Pain Drug Sales Market Share by Type (2018-2024)
Table 53. Global Diabetic Neuropathic Pain Drug Sales Market Share by Type (2024-2034)
Table 54. Global Diabetic Neuropathic Pain Drug Revenue (US$ Million) by Type (2018-2024)
Table 55. Global Diabetic Neuropathic Pain Drug Revenue (US$ Million) by Type (2024-2034)
Table 56. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Type (2018-2024)
Table 57. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Type (2024-2034)
Table 58. Global Diabetic Neuropathic Pain Drug Price (USD/Pcs) by Type (2018-2024)
Table 59. Global Diabetic Neuropathic Pain Drug Price (USD/Pcs) by Type (2024-2034)
Table 60. Global Diabetic Neuropathic Pain Drug Sales (K Pcs) by Application (2018-2024)
Table 61. Global Diabetic Neuropathic Pain Drug Sales (K Pcs) by Application (2024-2034)
Table 62. Global Diabetic Neuropathic Pain Drug Sales Market Share by Application (2018-2024)
Table 63. Global Diabetic Neuropathic Pain Drug Sales Market Share by Application (2024-2034)
Table 64. Global Diabetic Neuropathic Pain Drug Revenue (US$ Million) by Application (2018-2024)
Table 65. Global Diabetic Neuropathic Pain Drug Revenue (US$ Million) by Application (2024-2034)
Table 66. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Application (2018-2024)
Table 67. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Application (2024-2034)
Table 68. Global Diabetic Neuropathic Pain Drug Price (USD/Pcs) by Application (2018-2024)
Table 69. Global Diabetic Neuropathic Pain Drug Price (USD/Pcs) by Application (2024-2034)
Table 70. Astellas Pharma Inc. Corporation Information
Table 71. Astellas Pharma Inc. Description and Business Overview
Table 72. Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 73. Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Product
Table 74. Astellas Pharma Inc. Recent Developments/Updates
Table 75. AstraZeneca Plc Corporation Information
Table 76. AstraZeneca Plc Description and Business Overview
Table 77. AstraZeneca Plc Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 78. AstraZeneca Plc Diabetic Neuropathic Pain Drug Product
Table 79. AstraZeneca Plc Recent Developments/Updates
Table 80. BioDelivery Sciences International, Inc. Corporation Information
Table 81. BioDelivery Sciences International, Inc. Description and Business Overview
Table 82. BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 83. BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Product
Table 84. BioDelivery Sciences International, Inc. Recent Developments/Updates
Table 85. Boehringer Ingelheim GmbH Corporation Information
Table 86. Boehringer Ingelheim GmbH Description and Business Overview
Table 87. Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 88. Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Product
Table 89. Boehringer Ingelheim GmbH Recent Developments/Updates
Table 90. Daiichi Sankyo Company, Limited Corporation Information
Table 91. Daiichi Sankyo Company, Limited Description and Business Overview
Table 92. Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 93. Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Product
Table 94. Daiichi Sankyo Company, Limited Recent Developments/Updates
Table 95. Dong-A Socio Group Corporation Information
Table 96. Dong-A Socio Group Description and Business Overview
Table 97. Dong-A Socio Group Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 98. Dong-A Socio Group Diabetic Neuropathic Pain Drug Product
Table 99. Dong-A Socio Group Recent Developments/Updates
Table 100. Eli Lilly and Company Corporation Information
Table 101. Eli Lilly and Company Description and Business Overview
Table 102. Eli Lilly and Company Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 103. Eli Lilly and Company Diabetic Neuropathic Pain Drug Product
Table 104. Eli Lilly and Company Recent Developments/Updates
Table 105. Glenmark Pharmaceuticals Ltd. Corporation Information
Table 106. Glenmark Pharmaceuticals Ltd. Description and Business Overview
Table 107. Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 108. Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Product
Table 109. Glenmark Pharmaceuticals Ltd. Recent Developments/Updates
Table 110. Hydra Biosciences, Inc. Corporation Information
Table 111. Hydra Biosciences, Inc. Description and Business Overview
Table 112. Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 113. Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Product
Table 114. Hydra Biosciences, Inc. Recent Developments/Updates
Table 115. Immune Pharmaceuticals Inc. Corporation Information
Table 116. Immune Pharmaceuticals Inc. Description and Business Overview
Table 117. Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 118. Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Product
Table 119. Immune Pharmaceuticals Inc. Recent Developments/Updates
Table 120. Laboratorios Del Dr. Esteve S.A. Corporation Information
Table 121. Laboratorios Del Dr. Esteve S.A. Description and Business Overview
Table 122. Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 123. Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Product
Table 124. Laboratorios Del Dr. Esteve S.A. Recent Developments/Updates
Table 125. Lohocla Research Corporation Corporation Information
Table 126. Lohocla Research Corporation Description and Business Overview
Table 127. Lohocla Research Corporation Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 128. Lohocla Research Corporation Diabetic Neuropathic Pain Drug Product
Table 129. Lohocla Research Corporation Recent Developments/Updates
Table 130. Mertiva AB Corporation Information
Table 131. Mertiva AB Description and Business Overview
Table 132. Mertiva AB Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 133. Mertiva AB Diabetic Neuropathic Pain Drug Product
Table 134. Mertiva AB Recent Developments/Updates
Table 135. Novaremed Corporation Information
Table 136. Novaremed Description and Business Overview
Table 137. Novaremed Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 138. Novaremed Diabetic Neuropathic Pain Drug Product
Table 139. Novaremed Recent Developments/Updates
Table 140. Pharmaleads Corporation Information
Table 141. Pharmaleads Description and Business Overview
Table 142. Pharmaleads Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 143. Pharmaleads Diabetic Neuropathic Pain Drug Product
Table 144. Pharmaleads Recent Developments/Updates
Table 145. RAPID Pharmaceuticals AG Corporation Information
Table 146. RAPID Pharmaceuticals AG Description and Business Overview
Table 147. RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 148. RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Product
Table 149. RAPID Pharmaceuticals AG Recent Developments/Updates
Table 150. Relmada Therapeutics, Inc. Corporation Information
Table 151. Relmada Therapeutics, Inc. Description and Business Overview
Table 152. Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 153. Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Product
Table 154. Relmada Therapeutics, Inc. Recent Developments/Updates
Table 155. Sphaera Pharma Pvt. Ltd. Corporation Information
Table 156. Sphaera Pharma Pvt. Ltd. Description and Business Overview
Table 157. Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 158. Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Product
Table 159. Sphaera Pharma Pvt. Ltd. Recent Developments/Updates
Table 160. Theravasc, Inc. Corporation Information
Table 161. Theravasc, Inc. Description and Business Overview
Table 162. Theravasc, Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 163. Theravasc, Inc. Diabetic Neuropathic Pain Drug Product
Table 164. Theravasc, Inc. Recent Developments/Updates
Table 165. Key Raw Materials Lists
Table 166. Raw Materials Key Suppliers Lists
Table 167. Diabetic Neuropathic Pain Drug Distributors List
Table 168. Diabetic Neuropathic Pain Drug Customers List
Table 169. Diabetic Neuropathic Pain Drug Market Trends
Table 170. Diabetic Neuropathic Pain Drug Market Drivers
Table 171. Diabetic Neuropathic Pain Drug Market Challenges
Table 172. Diabetic Neuropathic Pain Drug Market Restraints
Table 173. Research Programs/Design for This Report
Table 174. Key Data Information from Secondary Sources
Table 175. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Diabetic Neuropathic Pain Drug
Figure 2. Global Diabetic Neuropathic Pain Drug Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Diabetic Neuropathic Pain Drug Market Share by Type in 2022 & 2034
Figure 4. AZD-5213 Product Picture
Figure 5. Clonidine Hydrochloride Product Picture
Figure 6. Duloxetine Hydrochloride DR Product Picture
Figure 7. E-52862 Product Picture
Figure 8. Filgrastim Product Picture
Figure 9. GERPOOI Product Picture
Figure 10. GRC-17536 Product Picture
Figure 11. Others Product Picture
Figure 12. Global Diabetic Neuropathic Pain Drug Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 13. Global Diabetic Neuropathic Pain Drug Market Share by Application in 2022 & 2034
Figure 14. Clinic
Figure 15. Hospital
Figure 16. Others
Figure 17. Global Diabetic Neuropathic Pain Drug Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 18. Global Diabetic Neuropathic Pain Drug Market Size (2018-2034) & (US$ Million)
Figure 19. Global Diabetic Neuropathic Pain Drug Sales (2018-2034) & (K Pcs)
Figure 20. Global Diabetic Neuropathic Pain Drug Average Price (USD/Pcs) & (2018-2034)
Figure 21. Diabetic Neuropathic Pain Drug Report Years Considered
Figure 22. Diabetic Neuropathic Pain Drug Sales Share by Manufacturers in 2022
Figure 23. Global Diabetic Neuropathic Pain Drug Revenue Share by Manufacturers in 2022
Figure 24. The Global 5 and 10 Largest Diabetic Neuropathic Pain Drug Players: Market Share by Revenue in 2022
Figure 25. Diabetic Neuropathic Pain Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 26. Global Diabetic Neuropathic Pain Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2034
Figure 27. North America Diabetic Neuropathic Pain Drug Sales Market Share by Country (2018-2034)
Figure 28. North America Diabetic Neuropathic Pain Drug Revenue Market Share by Country (2018-2034)
Figure 29. U.S. Diabetic Neuropathic Pain Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 30. Canada Diabetic Neuropathic Pain Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 31. Europe Diabetic Neuropathic Pain Drug Sales Market Share by Country (2018-2034)
Figure 32. Europe Diabetic Neuropathic Pain Drug Revenue Market Share by Country (2018-2034)
Figure 33. Germany Diabetic Neuropathic Pain Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 34. France Diabetic Neuropathic Pain Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 35. U.K. Diabetic Neuropathic Pain Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 36. Italy Diabetic Neuropathic Pain Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 37. Russia Diabetic Neuropathic Pain Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 38. Asia Pacific Diabetic Neuropathic Pain Drug Sales Market Share by Region (2018-2034)
Figure 39. Asia Pacific Diabetic Neuropathic Pain Drug Revenue Market Share by Region (2018-2034)
Figure 40. China Diabetic Neuropathic Pain Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 41. Japan Diabetic Neuropathic Pain Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 42. South Korea Diabetic Neuropathic Pain Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 43. India Diabetic Neuropathic Pain Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 44. Australia Diabetic Neuropathic Pain Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 45. Taiwan Diabetic Neuropathic Pain Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 46. Indonesia Diabetic Neuropathic Pain Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 47. Thailand Diabetic Neuropathic Pain Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 48. Malaysia Diabetic Neuropathic Pain Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 49. Philippines Diabetic Neuropathic Pain Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 50. Latin America Diabetic Neuropathic Pain Drug Sales Market Share by Country (2018-2034)
Figure 51. Latin America Diabetic Neuropathic Pain Drug Revenue Market Share by Country (2018-2034)
Figure 52. Mexico Diabetic Neuropathic Pain Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 53. Brazil Diabetic Neuropathic Pain Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 54. Argentina Diabetic Neuropathic Pain Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 55. Middle East & Africa Diabetic Neuropathic Pain Drug Sales Market Share by Country (2018-2034)
Figure 56. Middle East & Africa Diabetic Neuropathic Pain Drug Revenue Market Share by Country (2018-2034)
Figure 57. Turkey Diabetic Neuropathic Pain Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 58. Saudi Arabia Diabetic Neuropathic Pain Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 59. U.A.E Diabetic Neuropathic Pain Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 60. Global Sales Market Share of Diabetic Neuropathic Pain Drug by Type (2018-2034)
Figure 61. Global Revenue Market Share of Diabetic Neuropathic Pain Drug by Type (2018-2034)
Figure 62. Global Diabetic Neuropathic Pain Drug Price (USD/Pcs) by Type (2018-2034)
Figure 63. Global Sales Market Share of Diabetic Neuropathic Pain Drug by Application (2018-2034)
Figure 64. Global Revenue Market Share of Diabetic Neuropathic Pain Drug by Application (2018-2034)
Figure 65. Global Diabetic Neuropathic Pain Drug Price (USD/Pcs) by Application (2018-2034)
Figure 66. Diabetic Neuropathic Pain Drug Value Chain
Figure 67. Diabetic Neuropathic Pain Drug Production Process
Figure 68. Channels of Distribution (Direct Vs Distribution)
Figure 69. Distributors Profiles
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed